hemlibra 30mg/1ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 30 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika
hemlibra 60mg/0.4ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 60 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.4 ml. - hämophilie a - biotechnologika
hemlibra 105mg/0.7ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 105 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.7 ml. - hämophilie a - biotechnologika
hemlibra 150mg/1ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 150 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika
irinotecan actavis 20 mg/ml konzentrat zur herstellung einer infusionslösung
actavis group hf. - irinotecan hydrochlorid - irinotecan
irinotecan fresenius 20 mg/ml konzentrat zur herstellung einer infusionslösung
fresenius kabi austria gmbh - irinotecan hydrochlorid - irinotecan
irinotecan kabi 20 mg/ml konzentrat zur herstellung einer infusionslösung
fresenius kabi austria gmbh - irinotecan hydrochlorid - irinotecan
irinotecan hikma 20 mg/ml konzentrat zur herstellung einer infusionslösung
hikma farmaceutica (portugal) s.a. - irinotecan hydrochlorid - irinotecan
hemlibra
roche registration limited - emicizumab - hämophilie a - antihämorrhagika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kann verwendet werden in allen altersgruppen.
tecfidera
biogen netherlands b.v. - dimethylfumarat - multiple sklerose - immunsuppressiva - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).